-
Mashup Score: 3
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros - 1 month(s) ago
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor suppressor gene signature predicts early progression in #mHSPC. @MartaGdeH & @neerajaiims discuss clinical implications, the need for more frequent monitoring, patient counseling, and potential treatment strategies for pts with TSG-low signatures > https://t.co/M4Rtf5sRlO https://t.co/njIoO9thxJ
-
-
Mashup Score: 13Utilizing the Decipher mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross - 1 month(s) ago
Ashley Ross and David Morris discuss the use of the Decipher Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher can help stratify patients and guide treatment decisions, particularly in choosing between monotherapy, doublet, or triplet therapies. The discussion covers the STAMPEDE trial data, showing Decipher’s ability to predict treatment…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Utilizing the #Decipher mRNA score for risk stratification in #mHSPC. David Morris, MD, FACS @UA_Nashville and @ashleyrossmdphd @NUFeinbergMed discuss how Decipher can help stratify patients and guide treatment decisions. Full video > https://t.co/NbKWmpdQQZ @Decipher_VCYT https://t.co/6gZoYT3LGb
-
-
Mashup Score: 0
223Background: Apalutamide plus ADT (APA) demonstrated significantly improved overall survival (OS) compared to placebo plus ADT (PBO) for patients with mHSPC in the TITAN study (HR, 0.65; 95% CI, 0.53 to 0.79; P < .0001). At the time of final analysis, …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
@MPishvaian @DrGallent #TumorBoardTuesday @neerajaiims have extrapoled est median OS of 71.8 mos for overall #mCSPC w/apa ➡️ best fit models estimate median OS of 113.7 mos for apa + ADT in low-volume #mCSPC !! We’re jealous of these numbers in #GI oncology @MPishvaian https://t.co/GK9aEkLDJo
-
-
Mashup Score: 0PSMA-PET vs Conventional Imaging: A Post Hoc Analysis of EMBARK Patients With nmHSPC | GU Oncology Now - 1 month(s) ago
A recent cross-sectional post hoc analysis has examined the staging information obtained by PSMA-PET/CT in a patient cohort eligible for the EMBARK study.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔬 A recent cross-sectional post hoc analysis has examined the staging information obtained by PSMA-PET/CT in a cohort eligible for the #EMBARK trial to see what findings are present in patients with HR recurrent #nmHSPC on conventional imaging: https://t.co/x2AdHvwByK
-
Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer. #pcsm #mHSPC https://t.co/nQ9nJGaskQ